Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of CYP2C19 Polymorphism on Phenoconversion
NCT05264142Phase 1Unknown
- Start
- Apr 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of omeprazole in gastroesophageal reflux disease (GERD) (3 arms). Primary endpoint: Phenoconversion rate at 2 months. Status: unknown.
02
Drugs
omeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT05264142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05264142.